Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis

A pilot study

G. Ciprandi, I. Cirillo, A. Vizzaccaro, M. A. Tosca

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Background: Allergic rhinitis is characterized by an IgE-dependent inflammation. Nasal obstruction is related to allergic inflammation. Some antihistamines have been demonstrated to be capable of improving this nasal symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, inflammatory cells, and cytokine pattern in patients with seasonal allergic rhinitis (SAR), before and after treatment with levocetirizine, desloratadine, or placebo. Methods: Thirty patients with SAR were evaluated, 27 males and three females (mean age 26.9 ± 5.4 years). All of them received levocetirizine (5 mg/day), desloratadine (5 mg/day), or placebo for 2 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (TSS) (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Inflammatory cells were counted by conventional staining; IL-4 and IL-8 were measured by immunoassay on fluids recovered from nasal lavage. Results: Levocetirizine treatment induced significant symptom relief (P = 0.0009) and improved nasal airflow (P = 0.038). Desloratadine also relieved TSS (P = 0.01), but did not affect nasal airflow. Levocetirizine significantly reduced eosinophils (P = 0.029), neutrophils (P = 0.005), IL-4 (P = 0.041), and IL-8 (P = 0.02), whereas desloratadine diminished IL-4 only (P = 0.044). Placebo treatment did not significantly affect any evaluated parameters. Conclusions: This pilot study demonstrates the effectiveness of levocetirizine in: (i) relieving nasal symptoms, (ii) improving nasal airflow, (iii) reducing leucocyte infiltration, and (iv) diminishing cytokine levels. These findings are the first evidence of the effectiveness of levocetirizine in SAR.

Original languageEnglish
Pages (from-to)958-964
Number of pages7
JournalClinical and Experimental Allergy
Volume34
Issue number6
DOIs
Publication statusPublished - 2004

Fingerprint

Nasal Obstruction
Seasonal Allergic Rhinitis
Nose
Cytokines
Placebos
Interleukin-4
Interleukin-8
Nasal Lavage Fluid
Nasal Lavage
Rhinomanometry
Inflammation
Sneezing
Therapeutics
levocetirizine
Histamine Antagonists
Pruritus
Immunoassay
Double-Blind Method
Eosinophils
Immunoglobulin E

Keywords

  • Cytokines
  • Desloratadine
  • Inflammatory cells
  • Levocetirizine
  • Nasal obstruction
  • Seasonal allergic rhinitis

ASJC Scopus subject areas

  • Immunology

Cite this

Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis : A pilot study. / Ciprandi, G.; Cirillo, I.; Vizzaccaro, A.; Tosca, M. A.

In: Clinical and Experimental Allergy, Vol. 34, No. 6, 2004, p. 958-964.

Research output: Contribution to journalArticle

@article{4dec4e3725694cbb894f93405d069b26,
title = "Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: A pilot study",
abstract = "Background: Allergic rhinitis is characterized by an IgE-dependent inflammation. Nasal obstruction is related to allergic inflammation. Some antihistamines have been demonstrated to be capable of improving this nasal symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, inflammatory cells, and cytokine pattern in patients with seasonal allergic rhinitis (SAR), before and after treatment with levocetirizine, desloratadine, or placebo. Methods: Thirty patients with SAR were evaluated, 27 males and three females (mean age 26.9 ± 5.4 years). All of them received levocetirizine (5 mg/day), desloratadine (5 mg/day), or placebo for 2 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (TSS) (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Inflammatory cells were counted by conventional staining; IL-4 and IL-8 were measured by immunoassay on fluids recovered from nasal lavage. Results: Levocetirizine treatment induced significant symptom relief (P = 0.0009) and improved nasal airflow (P = 0.038). Desloratadine also relieved TSS (P = 0.01), but did not affect nasal airflow. Levocetirizine significantly reduced eosinophils (P = 0.029), neutrophils (P = 0.005), IL-4 (P = 0.041), and IL-8 (P = 0.02), whereas desloratadine diminished IL-4 only (P = 0.044). Placebo treatment did not significantly affect any evaluated parameters. Conclusions: This pilot study demonstrates the effectiveness of levocetirizine in: (i) relieving nasal symptoms, (ii) improving nasal airflow, (iii) reducing leucocyte infiltration, and (iv) diminishing cytokine levels. These findings are the first evidence of the effectiveness of levocetirizine in SAR.",
keywords = "Cytokines, Desloratadine, Inflammatory cells, Levocetirizine, Nasal obstruction, Seasonal allergic rhinitis",
author = "G. Ciprandi and I. Cirillo and A. Vizzaccaro and Tosca, {M. A.}",
year = "2004",
doi = "10.1111/j.1365-2222.2004.01960.x",
language = "English",
volume = "34",
pages = "958--964",
journal = "Clinical and Experimental Allergy",
issn = "0954-7894",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis

T2 - A pilot study

AU - Ciprandi, G.

AU - Cirillo, I.

AU - Vizzaccaro, A.

AU - Tosca, M. A.

PY - 2004

Y1 - 2004

N2 - Background: Allergic rhinitis is characterized by an IgE-dependent inflammation. Nasal obstruction is related to allergic inflammation. Some antihistamines have been demonstrated to be capable of improving this nasal symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, inflammatory cells, and cytokine pattern in patients with seasonal allergic rhinitis (SAR), before and after treatment with levocetirizine, desloratadine, or placebo. Methods: Thirty patients with SAR were evaluated, 27 males and three females (mean age 26.9 ± 5.4 years). All of them received levocetirizine (5 mg/day), desloratadine (5 mg/day), or placebo for 2 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (TSS) (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Inflammatory cells were counted by conventional staining; IL-4 and IL-8 were measured by immunoassay on fluids recovered from nasal lavage. Results: Levocetirizine treatment induced significant symptom relief (P = 0.0009) and improved nasal airflow (P = 0.038). Desloratadine also relieved TSS (P = 0.01), but did not affect nasal airflow. Levocetirizine significantly reduced eosinophils (P = 0.029), neutrophils (P = 0.005), IL-4 (P = 0.041), and IL-8 (P = 0.02), whereas desloratadine diminished IL-4 only (P = 0.044). Placebo treatment did not significantly affect any evaluated parameters. Conclusions: This pilot study demonstrates the effectiveness of levocetirizine in: (i) relieving nasal symptoms, (ii) improving nasal airflow, (iii) reducing leucocyte infiltration, and (iv) diminishing cytokine levels. These findings are the first evidence of the effectiveness of levocetirizine in SAR.

AB - Background: Allergic rhinitis is characterized by an IgE-dependent inflammation. Nasal obstruction is related to allergic inflammation. Some antihistamines have been demonstrated to be capable of improving this nasal symptom. Objective: The aim of this pilot study was to evaluate nasal symptoms, nasal airflow, inflammatory cells, and cytokine pattern in patients with seasonal allergic rhinitis (SAR), before and after treatment with levocetirizine, desloratadine, or placebo. Methods: Thirty patients with SAR were evaluated, 27 males and three females (mean age 26.9 ± 5.4 years). All of them received levocetirizine (5 mg/day), desloratadine (5 mg/day), or placebo for 2 weeks. The study was double-blind, parallel-group, placebo-controlled, and randomized. Total symptom score (TSS) (including: rhinorrhea, nasal itching, sneezing, and nasal obstruction) was assessed before and after treatment. Rhinomanometry, nasal lavage, and nasal scraping were performed in all subjects before and after treatment. Inflammatory cells were counted by conventional staining; IL-4 and IL-8 were measured by immunoassay on fluids recovered from nasal lavage. Results: Levocetirizine treatment induced significant symptom relief (P = 0.0009) and improved nasal airflow (P = 0.038). Desloratadine also relieved TSS (P = 0.01), but did not affect nasal airflow. Levocetirizine significantly reduced eosinophils (P = 0.029), neutrophils (P = 0.005), IL-4 (P = 0.041), and IL-8 (P = 0.02), whereas desloratadine diminished IL-4 only (P = 0.044). Placebo treatment did not significantly affect any evaluated parameters. Conclusions: This pilot study demonstrates the effectiveness of levocetirizine in: (i) relieving nasal symptoms, (ii) improving nasal airflow, (iii) reducing leucocyte infiltration, and (iv) diminishing cytokine levels. These findings are the first evidence of the effectiveness of levocetirizine in SAR.

KW - Cytokines

KW - Desloratadine

KW - Inflammatory cells

KW - Levocetirizine

KW - Nasal obstruction

KW - Seasonal allergic rhinitis

UR - http://www.scopus.com/inward/record.url?scp=3042533417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042533417&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2222.2004.01960.x

DO - 10.1111/j.1365-2222.2004.01960.x

M3 - Article

VL - 34

SP - 958

EP - 964

JO - Clinical and Experimental Allergy

JF - Clinical and Experimental Allergy

SN - 0954-7894

IS - 6

ER -